Product Name:
JAK1-pT1107
Product Number:
ab-pk895
Target Full Name: Janus protein-tyrosine kinase 1
Target Alias: EC 2.7.10.2; JAK1A; Janus kinase 1
Product Type Specific: JAK1 protein kinase phosphosite-specific antibody
Antibody Code: PK895
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T1107
Protein UniProt: P23458
Protein SigNET: JAK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human JAK1
Antibody Immunogen Sequence: LVN(pT)LKE(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues L1104 to E1110. The effect of T1107 phosphorylation is unknown. Its phosphorylation has been observed in only one mass spectrometry study recorded in PhosphoSitePlus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus Macaque | Dog | Mouse | Frog | Zebra fish.
Related Product 1: JAK2Selectide kinase substrate peptide (Cat. No.: PE-01BHR90)
Related Product 2: JAK3Selectide kinase substrate peptide (Cat. No.: PE-01BHS95)
Related Product 3: IRS1 (891-902) KinSub kinase substrate peptide (Cat. No.: PE-01AQD95)
Related Product 4: JAK1 expression antibody (Cat. No.: AB-NK084-3)
Related Product 5: JAK1 expression antibody (Cat. No.: AB-NK084-4)
Related Product 6: JAK1 expression antibody (Cat. No.: AB-NK084-5)
Related Product 7: JAK1 Y1022 phosphorylation antibody (Cat. No.: AB-PK126)
Related Product 8: JAK1 Y1034+Y1035 phosphorylation antibody (Cat. No.: AB-PK884)
Related Product 9: Tyk2 Y292 phosphorylation antibody (Cat. No.: AB-PK846)
Related Product 10: Tyk2 Y1054+Y1055 phosphorylation antibody (Cat. No.: AB-PK845)
Scientific Background: JAK1 is a protein-tyrosine kinase of the TK group and JAKA family. It is a non-receptor kinase that functions in the IFN-alpha/beta/gamma intracellular signal pathway. It features seven conserved JAK homology (JH) domains. The C-terminal JH1 is the active tyrosine kinase domain, while the adjacent JH2 appears to be a nonfunctional "pseudokinase" domain with regulatory roles. JAK1 has also been shown to interact with the interleukin-2 (IL-2) receptor. It is essential for signaling for IL-2 family (IL-2, 7, 9, 15), IL-4 family (IL-4, 13), gp130 family (IL-6, LIF), and interferons (IFN-a/b) and IFN-g). The JAK1 protein is typically membrane-associated and is widely expressed across different tissues. JAK1 also functions upstream of STAT transcription factors, specifically STAT3, acting to activate the proteins and promote gene transcription. Phosphorylation of Tyr-940 inhibits phosphotransferase activity. JAK1 may be an oncoprotein (OP). Abnormal activity of STAT3 is implicated in the oncogenesis of several cancer types, including colorectal cancer and non-small cell lung cancer. JAK1 has been implicated in promoting the survival, invasion, and migration of colorectal cancer and non-small cell lung cancer cells due to over activation of STAT transcription factors resulting in the aberrant expression of certain downstream genes, such as Bcl-2, p21, p27, E-cadherin, VEGF, and MMPs. In addition, somatic mutations in the JAK1 gene have been observed in patients with acute myeloid leukemia (AML), including both T478S and V623A substitution mutations. The mutant JAK1 proteins displayed significantly enhanced activation of downstream STAT1 in response to type 1 interferon treatment, as well as increased activation of multiple dowstream intracellular signalling pathways. Truncating mutations of JAK1 have been observed in several cancer types, with 68% of the specimens coming from gynecologic cancers. Cancer cells with mutant truncated JAK1 protein are defective in IFN-gamma induced expression of LMP2 and TAP1, which inhibits the presentation of tumour antigens to be recognized by the immune system. Therefore, these truncating mutations are hypothesized to promote the ability of tumour cells to evade the immune system, enabling tumour survival. Piceatannol is a known JAK1 inhibitor. This description may include information annotated by UniProt and/or Google AI.